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Abstract 
 
Introduction 
Fetal fibronectin (fFN) is a validated test for assessing risk of preterm birth (PTB) for women 
presenting with symptoms. Our aim was to evaluate the accuracy of fFN to detect the risk of 
PTB in asymptomatic women.  
Material and methods 
Searches were conducted to identify studies where fFN was performed in asymptomatic 
women beyond 22 weeks’ gestation. EMBASE, MEDLINE, CINHAL, AMED and BNI were 
searched between 2005 and 2017. Studies before 2005 were identified from a published 
systematic review. Women were grouped as singleton pregnancies, with and without risk 
factors for PTB, and multiple pregnancy. Quality assessment was performed using 
QUADAS-2. When possible, data were pooled using a hierarchical, bivariate random effects 
model. 
Results 
Fifteen studies met the inclusion criteria: six studies of singleton pregnancies in women 
without risk factors (1,236 women), four in women with risk factors for PTB (2,628 women) 
and five studies were of multiple pregnancy (1,427 women). The pooled sensitivity and 
specificity of fFN in ‘no risk factors singletons’ were 0.48 (95% CI 0.20–0.77), and 0.96 
(95% CI 0.86–0.99) respectively. The likelihood ratio of a positive test result was 12 (95% CI 
4.70-30.68). The pooled sensitivity and specificity of fFN in ‘risk factors singletons’ were 
0.34 (95% CI 0.24–0.43), and 0.91 (95% CI 0.88–0.93). Accuracy of fFN in multiple 
pregnancies was inconclusive. 
Conclusion 
Our findings suggest in asymptomatic singleton pregnancies without risk factors a positive 
fFN result indicates a large shift from pre to post-test probability, possibly identifying women 
at increased risk of PTB. 
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Key Message  
Fetal fibronectin is an onsite test available evaluating the risk for preterm birth. Its 
performance in asymptomatic women is undetermined. A positive result in women carrying a 
singleton pregnancy without risk factors for preterm birth may predict early delivery.   
 
 
Introduction 
Preterm birth (PTB) is defined by the World Health Organisation as ‘birth occurring prior to 
37 completed weeks of gestation’ (1) and is the leading cause of perinatal morbidity and 
mortality worldwide, in both singleton and multiple pregnancies (2, 3).  Spontaneous preterm 
births occurs in 60-70% of all preterm births (4) with approximately 15 million babies born 
preterm in 2010 (1). The incidence of PTB varies widely ranging from 5-13% (3, 5). The 
neonatal morbidity, its long-term sequelae and the mortality associated with PTB have huge 
implications for clinical resources and convey a significant economic burden (4). Although 
the rates of survival have improved (3), the rate of disability for survivors has remained 
unchanged (4, 6). 
 
None of the available scoring systems accurately identify asymptomatic women at risk of 
spontaneous PTB (4, 7). Identifying asymptomatic women at risk of PTB could be beneficial, 
as it would allow for timely interventions to reduce perinatal morbidity, such as the 
administration of corticosteroids and access to neonatal intensive care facilities (5). An 
objective test for predicting risk of PTB is fetal fibronectin (fFN), an adhesion basement 
membrane protein found in cervicovaginal secretions (8, 9). fFN levels are routinely found in 
cervicovaginal secretions up to 20 weeks of gestation but after this, it is rarely found until late 
in pregnancy and can be an indication of impending labour (9). fFN has been developed as a 
bedside test for identifying women at risk of preterm labour and it is widely used in high-
income settings, such as the United Kingdom (10) for triaging women with symptoms. The 
aim of this review was to determine the accuracy of fFN for identifying the risk of PTB in 
asymptomatic pregnant women, as the published data in this area have not been 
systematically synthesised.  
 
Material and Methods 
This review was conducted in compliance with the current standards for test accuracy 
research (11, 12); reported according to the Preferred Reporting Items for Systematic 
Reviews (PRISMA) guidelines (13) and recommendations of reporting test accuracy 
systematic reviews (14). It was prospectively registered (PROSPERO number: 
CRD42015023779). 
 
 
 
 
 
Literature search 
A systematic search of primary studies in EMBASE, MEDLINE, CINHAL, AMED and BNI 
was undertaken prospectively and limited to studies published between 2005 and 2015. The 
initial search was performed on 29 January 2015 and then updated on 01 February 2017 with 
no language restrictions. The following terms, associated synonyms and right-hand truncation 
were used for the searches: ‘pregnancy’, ‘antenatal’, ‘fetal proteins’ and ‘fibronectins’ 
(Supporting Information, Table S1). The database search was complemented by the 
comprehensive reference check of the included studies. Relevant studies published prior to 
2005 were identified from a previous comprehensive search published in a Health 
Technology Assessment report in 2009 (4). Studies of cross-sectional, longitudinal and case-
control design studies were included.  
 
Study selection and data extraction 
Two reviewers (FDS and JD) independently reviewed titles and abstracts and identified 
citations fulfilling the pre-determined selection criteria. Full text versions of the selected 
citations were reviewed for their eligibility. Any disagreements were resolved through 
consensus. The inclusion criteria were: i) pregnant women carrying either singleton or 
multiple pregnancies without symptoms of PTB; ii) fFN sampling (index test) undertaken 
after 22 weeks of gestation using a validated method (15, 16); and, iii) the use of a threshold 
of 50 ng/ml for a positive test, as per the manufacturer’s instructions (15). When studies 
used serial testing, a woman was considered to have a positive fFN test if a level of 50 
ng/ml was documented at any point during the testing period. If a study reported multiple 
thresholds, the data for the ≥50 ng/ml cut-off were used. 
 
Studies including women identified as having symptoms of preterm labour (such as uterine 
contractions, preterm premature rupture of membranes or insertion of a rescue cervical 
cerclage) were excluded. The reference standard for PTB was defined as birth prior to 37 
weeks of gestation (3). 
 
Data were extracted onto a piloted data extraction sheet independently and in duplicate by 
two reviewers (FDS and JD). Data were collected on population characteristics (age, 
ethnicity, education, parity, smoking status, risk factors for PTB), description of the index 
test including the threshold used for a positive test, how the gestational age at testing was 
 
 
defined, the definition of PTB used by the study authors and the results of the index test (true 
positives, true negatives, false positives and false negative) to allow creation of a 2x2 table.  
Women with a singleton pregnancy were grouped according to the presence of risk factors 
for PTB (with or without). The third group comprised women with multiple pregnancies 
(twins or triplets). The considered risk factors for PTB were: previous PTB, smoking or other 
risk factors as defined in the primary studies. All data were tabulated, crosschecked and any 
discrepancies were discussed between reviewers, involving a third reviewer (ER) when 
necessary. The risk of bias and applicability of the included studies were assessed 
independently by two reviewers (FDS and JD) using the QUADAS-2 tool (12). The 
applicability is determined by how similar or different are the population, the index test and 
the reference standard to that of the review question (12).  
 
Data synthesis 
The data were plotted using RevMan (Version 5.3. Copenhagen: The Nordic Cochrane 
Centre, The Cochrane Collaboration, 2014) and, where possible, pooled using STATA 
software (StataCorp. 2011. Version 12. College Station, TX: StataCorp LP) within the 
predefined subgroups. When a sufficient number of studies were available, we pooled the 
accuracy parameters using a bivariate, hierarchical model (random effect) (17). If fewer than 
four studies were available, a univariate model was used (18). We calculated sensitivity, 
specificity and likelihood ratios for positive and negative test results with 95% confidence 
intervals (CIs). Heterogeneity was investigated visually from forest plots of sensitivity and 
specificity estimates derived from individual studies. Sensitivity analysis concerning the type 
of used analyser was conducted as a part of a post-hoc exploration. We did not attempt to 
assess publication bias due to the lack of consensus over the reliability of currently available 
methods (19, 20). Moreover, we did not have a sufficient number of studies in order to run a 
meaningful assessment of publication bias (21).   
 
Results  
There were 2,020 studies identified following the electronic search and 18 studies identified 
from the Health Technology Assessment report (4). After duplicates removal, 516 studies 
were identified and screened for their eligibility. Ninety full-text papers were reviewed, and 
15 studies were subsequently included (Figure 1) (16, 22-35). The inter-rater reliability for 
the study selection was good (=0.8).  
 
 
 
Included studies recruited women with a history of previous PTB (n = 5), (16, 22, 24, 25, 28) 
women who were smokers (n = 2), (22, 25) women with cervical cerclage or women who 
were being followed-up in preterm birth surveillance clinics for other risk-factors (n = 6) (16, 
22, 24, 25, 28, 29). There was variation in the devices used by studies included in this review 
for measuring fFN. Seven studies used Adeza Biomedical, Sunnyvale®, (16, 26-28, 32-34) 
five studies used Hologic® (22, 25, 30, 31, 35) and three studies (23, 24, 29) did not provide 
information regarding the device used. Ten studies collected samples for fFN testing 
according to the manufacturer’s instructions (‘standard’ fFN). Five studies used a blind 
method for obtaining samples for fFN testing (‘blind’ fFN) (Table 1).  
 
There was also variation in the timing of sampling. In singleton pregnancy studies, six used 
serial sampling (timing not specified in one study (28); every 2, 2-3, 2-4 or every 2-6 weeks 
in the five remaining studies (16, 25, 27, 32, 33) with samples collected between 22 and 36 
weeks of gestation. Three studies used a single sample of fFN taken between 22-28, 26-28 or 
at 28 weeks of gestation (22, 23, 26). For the twin studies, fFN testing was performed every 
2-4 weeks between 22-32 weeks of gestation in all three included studies. Two studies 
included women with a triplet pregnancy both used serial testing every 2-3 weeks from 22-32 
weeks of gestation. All the studies except one (22) used a pre-specified threshold of ≥50 
ng/ml to denote a positive test result. 
 
The reference standard used was gestation at birth. There was variation in the way the 
reference standard was calculated. Ten of studies used the last menstrual period to calculate 
the gestational age, which was confirmed by a first or second trimester ultrasound. The 
ultrasound result took precedence if there was a discrepancy (22-24, 26, 28, 30-34). Five 
studies did not specify how the gestational age was calculated (16, 25, 27, 29, 35). Full 
details of studies included in this systematic review are presented in Supporting Information, 
Table S2. 
 
Quality Assessment 
The risk of bias in all four domains of the QUADAS-2 tool was considered to be low in the 
majority of the studies. There were also low applicability concerns for most of the studies 
(Figure 2). Quality assessment for singleton pregnancy studies is presented for those studies 
included in the meta-analysis only.  
 
 
 
In the studies of fFN testing in women carrying singleton pregnancies without risk factors, 
the risk of bias due to the implementation of the index test and reference standard was 
assessed as low in the majority of the studies (5/6). In each QUADAS-2 domain, there was 
one study classified as at high risk of bias. The concern over the applicability of the studies 
was presented with respect to patient selection, index test and reference standard was 
assessed as low in the majority of the included studies.  
 
All three studies of women carrying singleton pregnancies with risk factors for PTB were 
classified as low risk of bias for the index test, reference standard, and flow and timing 
(Figure 2). In one study (28), the description of patient selection raised concerns; hence the 
study was classified as high risk of bias in this domain. There was no concern over the 
applicability in any of the studies with respect to patient selection or how the index test was 
taken. In two cases (25, 28) the description was insufficient to assess the studies applicability 
with respect to the reference standard.  
 
The majority of studies with twin or triplet pregnancies were classified as at low risk of bias 
and their applicability to the review question (Figure 2).  In one study (24) the description of 
patient selection raised concerns leading to its classification as at high risk of bias in this 
domain. Two out of five studies were labelled as high risk of bias due to the implementation 
of index test. One study was assessed to be at high risk of bias over applicability of the index 
test (24). 
 
Accuracy of fFN in asymptomatic singletons without risk factors for PTB 
Nine studies reported accuracy data for fFN in singleton pregnancies of which six (1,236 
women) (23, 26, 27, 32-34) included women without risk factors for PTB (Figure 3). The 
pooled sensitivity and the specificity were 0.48 (95% CI 0.20–0.77), and 0.96 (95% CI 0.86–
0.99) (Figure 4). The visual inspection of heterogeneity showed a greater variability in the 
sensitivity measures than the specificity. The 95% prediction region covered over half of the 
ROC space. The calculated likelihood ratio of a positive test result was 12.01 (95% CI 4.70-
30.68), the likelihood ratio of a negative test result was 0.54 (95% CI 0.30-0.97). The 
sensitivity analysis with studies that used only Adeza Biomedical analyser showed a change 
in fFN sensitivity 0.60 (95% CI 0.34–0.81) with a minor change in the pooled specificity 0.93 
(95% CI 0.83–0.97). 
 
 
 
 
 
Accuracy of fFN in asymptomatic singletons with risk factors for PTB  
Three studies included women carrying singleton pregnancy with risk factors for PTB 
contributed to our meta-analyses (22, 25, 28). One study (16), was excluded from the meta-
analyses due to the definition of the reference standard used (PTB prior to 34 weeks of 
gestation). The studies all included women with a previous history of PTB, two included 
women who were smokers and all included women with other risk factors such as previous 
second trimester miscarriage, previous cervical surgery, women with an incidental short 
cervix and women with a cervical cerclage in situ or history of a previous cerclage. The 
pooled sensitivity and the specificity were 0.34 (95% CI 0.24-0.43), and 0.91 (95% CI 0.88-
0.93). The likelihood ratio of a positive test result was 3.47 (95% CI 2.84-4.24). The 
likelihood ratio of a negative test result was 0.75 (95% CI 0.68-0.82). 
 
Accuracy of fFN in asymptomatic women with multiple pregnancy 
None of the studies that evaluated fFN in women with multiple pregnancies used a reference 
standard defined as birth before 37 weeks. The majority of included studies used less than 32 
weeks as the definition of PTB in multiple pregnancy, therefore this definition was adopted 
post hoc. Three studies (1,332 women) included women with twin gestations (24, 29, 31). 
The prevalence of PTB in these studies ranged from 6.9 - 30.0%. Sensitivity ranged from 
0.29-0.41 and specificity ranged from 0.92-0.96. Two studies (95 women) were conducted in 
women carrying triplet pregnancies (30, 35). The prevalence of PTB in this population 
ranged from 17.9-23.2%. Sensitivity ranged from 0.60 - 0.63 and specificity ranged from 
0.92-0.96 (Table 1). 
 
Discussion 
Summary of results  
This systematic review is the first to assess the performance of fFN in asymptomatic pregnant 
women without risk factors for preterm delivery. In singleton pregnancy without risk factors 
for PTB, a positive result can be indicative of an increased risk of premature delivery. Based 
on the findings of this review the test is unlikely to provide clinically useful information 
when used in women with documented risk factors for PTB (e.g. previous second-trimester 
miscarriage, previous cervical surgery). The accuracy of fFN in women with multiple 
 
 
pregnancy was inconclusive. 
  
 
Strengths and Limitations  
The main strengths of this review include the use of strict published criteria for performing 
test accuracy systematic reviews, using a prospective protocol and conducting a 
comprehensive literature search. We contacted authors of included studies where needed for 
clarifications and included responses within our assessment processes. 
 
The main limitations of this review are related to the heterogeneity of the data within the 
included studies. We included studies undertaken in the context of preterm birth surveillance 
clinics. Women in these clinics are a heterogeneous population, including some women 
having a history of PTB or having a cervical cerclage in situ and others with a different 
spectrum of risk factors. Including data collected in these clinics may have introduced 
selection bias into our analyses (4). Despite the risk of bias, we were keen not to exclude 
these data, as they reflection the current models of antenatal care for women with known risk 
factors for PTB in high income settings (5).   
 
In this review, we limited our inclusion criteria to studies where fFN was tested after 22 
weeks of gestation, based on the manufactures’ instructions (15). We chose 22 weeks 
gestation as the lowest gestational age for testing, based on how a positive result would be 
managed clinically (5).  There are a number of recently published studies where fFN testing 
has occurred before 22 weeks of gestation, however the performance of fFN in this context 
and the clinical management protocols for a positive result are not well established. We 
included studies where a ‘blind method’ for collecting fFN was used, where samples for fetal 
fibronectin measurement were taken without the insertion of a speculum and visualization of 
the posterior fornix (16). This technique has been validated and its performance deemed 
similar to the direct visualisation method (16) hence our decision to include primary studies 
using this technique in our review. However, we cannot exclude the possibility that inclusion 
of this alternative method alongside traditional sampling techniques may have introduced 
bias into the estimates of test performance in our meta-analyses. 
 
In twin pregnancies, fFN testing is known to have a low to moderate accuracy in predicting 
PTB (2), but is likely to be a stronger predictor than cervical length measurement (36). Birth 
 
 
before 32 weeks was the definition of PTB used in the studies of multiple pregnancies as the 
reference standard and was adopted by us post-hoc. This was a deviation from our study 
protocol which was necessary to allow pooling of study findings. We identified three studies 
meeting our inclusion criteria, however despite our efforts to widen inclusion there was 
insufficient data to permit meta-analyses in this subgroup. As a result, we cannot comment on 
the performance of fFN for predicting PTB in twin or triplet pregnancies.  
 
Interpretation 
Many primary studies looking into the accuracy of fFN for predicting PTB in asymptomatic 
pregnant women are inadequately powered to estimate the accuracy of the test. This is largely 
due to the varying prevalence of PTB in individual study samples (37).  
Our results show that fFN testing in asymptomatic women, without any risk factors had the 
highest likelihood ratio (12.01). As a general rule, a positive likelihood ratio >10 or a 
negative likelihood ratio <0.1, is associated with a large shift from pre-test to post-test 
probability (38) demonstrating that the test is useful in predicting the outcome. Likelihood 
ratios (sensitivity/(1-specificity) are also less dependent on the condition being present or not 
in the population by attributing equal weights to sensitivity and specificity. (39) When in a 
certain population there are a significant number of individuals without the condition being 
tested (such as in a low risk obstetric population), the number of those correctly identified as 
having the condition or not, is described by the specificity of the test (39). However, using 
fetal fibronectin as a single screening test in pregnant women without any risk factors for 
PTB is unlikely to be feasible or acceptable (40). It is more likely that fetal fibronectin could 
be used in combination with other predictors of PTB (for example cervical length 
measurement) to increase the odds of detecting women at risk of PTB (41). 
 
There were a number of studies in our review where fFN samples were collected at different 
gestational ages and many studies employed a serial fFN sampling strategy. In these 
instances, we used the latest gestational age of testing as our index test. It is beyond the scope 
of this review to suggest an optimal time for sample collection. Similarly, our review cannot 
suggest the optimum number of samples required within a serial sampling strategy  to 
identify those women at risk and allow for timely interventions. These questions will require 
further primary research to be addressed.  
 
 
 
A previous report (40) suggested that positive fFN results between 24 and 28 gestational 
weeks are helpful in identifying women at high-risk of PTB during the a period of time where 
the neonatal morbidity and mortality is high. Our systematic review did not look at testing of 
fFN within these gestational ages as a subgroup and therefore we cannot make any 
recommendations as to whether testing of women with risk factors at these gestations affects 
outcomes. A study by Jwala et al. in 2016 (42) suggested that quantitative fFN and and 
cervical length measurement in asymptomatic women without risk factors for PTB increase 
the sensitivity of fFN, but whether this is useful clinically has not been determined.  A recent 
prospective study comparing women with previous history of PTB to women without a 
history of PTB found that a positive fFN was the best predictor for recurrence of PTB,  
increasing the recurrence risk between two to four-fold compared to women without a 
positive fFN result (43). There are however, many conflicting data on whether fFN is useful 
for care delivery in women with risk factors for PTB (44), which we postulate is secondary to 
poor quality primary research in this area.  
 
Our systematic review showed that fFN is a useful test for identifying women at risk of PTB 
without any pre-existing risk factors. This is based on the accuracy measure obtained for the 
likelihood ratio of a positive test rather than the pooled sensitivity. fFN may also be useful in 
managing women with risk factors for PTB, however, it is likely that these women are cared 
for in specialist centres, where other strategies of risk identification such as cervical length 
measurement are employed, which may be more helpful in stratifying risk for women with 
risk factors for PTB (45). 
 
Conclusion  
There is currently no evidence supporting the use of fFN testing in asymptomatic women (3, 
46). Our systematic review suggests that in women with singleton pregnancies without risk 
factors for PTB, a positive fFN may be predictive of preterm birth, but should be used with 
caution. Further good quality research is needed to determine the usefulness of fFN testing in 
the pathway of care for women without risk factors who are asymptomatic for PTB.    
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